Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update
Product revenue for the first six months of 2023 increased to $22.7 million, compared to $3.9 million for the same period in 2022Investors, including Teva Pharmaceuticals, subscribed to Alvotech’s subordinated convertible bonds for an aggregate amount of $140 million in July 2023Expanded its existing commercialization partnerships with Teva Pharmaceuticals for the US and with Advanz Pharma for EuropeSettlement reached with Johnson & Johnson securing a US license entry date for AVT04, Alvotech’s